Bottom line
PRHSX vs QAAGZX: the short answer
PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and QAAGZX (T. Rowe Price Health Sciences Portfolio) have nearly the same top holdings — their top 25 positions are about 98% the same by weight.
PRHSX is cheaper at 0.83% vs 0.86% — a difference of $3.00 a year per $10,000 invested.
Over five years, PRHSX returned +4.2% a year vs +4.1% for QAAGZX.
Updated Nov 19, 2026
PRHSX vs QAAGZX side by side
| PRHSX | QAAGZX | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | T. Rowe Price | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.83% | 0.86% |
| Annual cost per $10k | $83 | $86 |
| 10-yr cost on $10k (prospectus) | $1,025 | $1,061 |
| Max front load | — | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +17.7% | +18.1% |
| 5-yr return (annualized) | +4.2% | +4.1% |
| 10-yr return (annualized) | +9.1% | +9.0% |
| Best quarter | +23.5% | +23.4% |
| Worst quarter | −15.8% | −15.8% |
| Net assets (fund) | $11.9B | $751.7M |
| Number of holdings | 279 | 277 |
| Portfolio turnover | 62% | 65% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PRHSX | QAAGZX | Difference |
|---|---|---|---|
| 2025 | +17.7% | +18.1% | −0.4% |
| 2024 | +1.8% | +1.7% | +0.2% |
| 2023 | +3.1% | +3.0% | +0.1% |
| 2022 | −12.2% | −12.5% | +0.3% |
| 2021 | +13.3% | +13.1% | +0.2% |
| 2020 | +30.1% | +29.6% | +0.5% |
| 2019 | +29.1% | +29.0% | +0.2% |
| 2018 | +1.2% | +1.1% | +0.1% |
| 2017 | +28.0% | +27.6% | +0.4% |
| 2016 | −10.4% | −10.5% | +0.1% |
Source: Fund prospectus bar charts
Holdings overlap
24 of PRHSX's top 25 holdings also appear in QAAGZX's top 25.
| Holding | PRHSX | QAAGZX |
|---|---|---|
| Eli Lilly & Co | 14.28% | 14.06% |
| Johnson & Johnson | 6.63% | 6.64% |
| Unitedhealth Group Inc | 5.99% | 5.88% |
| Abbvie Inc | 5.10% | 5.12% |
| Merck & Co. Inc. | 4.01% | 4.00% |
| Gilead Sciences Inc | 2.82% | 2.79% |
| Thermo Fisher Scientific Inc | 2.52% | 2.53% |
| Vertex Pharmaceuticals Inc | 2.28% | 2.26% |
| Bristol-myers Squibb Co | 2.11% | 2.12% |
| Abbott Laboratories | 1.89% | 1.91% |
| Intuitive Surgical Inc | 1.87% | 1.89% |
| Amgen Inc | 1.82% | 1.80% |
| Stryker Corp | 1.78% | 1.78% |
| Elevance Health Inc | 1.53% | 1.54% |
| Natera Inc | 1.44% | 1.44% |
Source: SEC Form N-PORT
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
QAAGZX top 10
- Eli Lilly & Co — 14.06%
- Johnson & Johnson — 6.64%
- Unitedhealth Group Inc — 5.88%
- Abbvie Inc — 5.12%
- Merck & Co. Inc. — 4.00%
- Gilead Sciences Inc — 2.79%
- Thermo Fisher Scientific Inc — 2.53%
- Vertex Pharmaceuticals Inc — 2.26%
- Bristol-myers Squibb Co — 2.12%
- Abbott Laboratories — 1.91%
FAQ
What is the difference between PRHSX and QAAGZX?
Which is cheaper, PRHSX or QAAGZX?
Should I own both PRHSX and QAAGZX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.